High-precision immune-related plasma proteomics profiling predicts response to immunotherapy in patients with triple-negative breast cancer.

ABSTRACT:

Objective

While immunotherapy holds great potential for triple-negative breast cancer (TNBC), the lack of non-invasive biomarkers to identify beneficiaries limits the application.

Methods

Paired baseline, on-treatment, and post-treatment plasma samples were collected from 195 TNBC patients receiving anti-PD-1 immunotherapy in this retrospective study conducted at the Fudan University Shanghai Cancer Center (FUSCC) for sequential high-precision proteomic profiling.

Results

ARG1, NOS3, and CD28 were identified as plasma proteins significantly associated with the response to immunotherapy in neoadjuvant settings or in advanced stages of TNBC. Matched single-cell RNA sequencing data were incorporated to correlate peripheral plasma with the tumor microenvironment. Furtherm

SUBMITTER: Xiao Y 

PROVIDER: S-EPMC12302270 | biostudies-literature | 2025 Jul

REPOSITORIES: biostudies-literature